Allakos (NASDAQ:ALLK) Earns “Neutral” Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their neutral rating on shares of Allakos (NASDAQ:ALLKFree Report) in a research report sent to investors on Thursday, Benzinga reports.

Allakos Trading Up 7.8 %

Shares of Allakos stock opened at $1.11 on Thursday. The firm has a market cap of $98.28 million, a P/E ratio of -0.45 and a beta of 0.93. Allakos has a 12 month low of $0.98 and a 12 month high of $5.64. The stock’s fifty day moving average price is $1.20 and its 200-day moving average price is $1.58.

Allakos (NASDAQ:ALLKGet Free Report) last issued its earnings results on Thursday, May 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.09). Analysts forecast that Allakos will post -1.24 earnings per share for the current year.

Institutional Investors Weigh In On Allakos

A number of hedge funds have recently made changes to their positions in the stock. Aristides Capital LLC purchased a new stake in shares of Allakos during the 4th quarter valued at $153,000. BNP Paribas Financial Markets boosted its holdings in Allakos by 1,041.1% in the first quarter. BNP Paribas Financial Markets now owns 205,663 shares of the company’s stock worth $259,000 after acquiring an additional 187,640 shares in the last quarter. Pennant Investors LP purchased a new stake in shares of Allakos during the fourth quarter worth about $508,000. GSA Capital Partners LLP acquired a new position in shares of Allakos during the first quarter valued at about $929,000. Finally, Ikarian Capital LLC raised its position in shares of Allakos by 293.4% in the 1st quarter. Ikarian Capital LLC now owns 932,675 shares of the company’s stock valued at $1,175,000 after purchasing an additional 695,619 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

About Allakos

(Get Free Report)

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.

Read More

Analyst Recommendations for Allakos (NASDAQ:ALLK)

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with's FREE daily email newsletter.